Writer-director John Krasinski's A Quiet Place returns in 2027 for Part 3, with stars Emily Blunt, Millicent Simmonds, Noah ...

Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...

Both dosage regimens of amlitelimab were associated with statistically significant improvements in skin clearance and disease severity vs placebo in the US estimand. Topline data were announced from ...

Topline Data from Three Phase 3 Studies Evaluating DT120 Orally Disintegrating Tablet (ODT) for GAD and MDD Expected in 2026: Voyage in 2Q, Panorama in 2H, and Emerge Mid-Year Company Presenting at ...

The U.S. Space Force has awarded SpaceX nine task orders worth $739 million combined to provide Lane 1 launch services under the National Security Space Launch, or NSSL, program’s third phase. The ...

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated ...

Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...

The last time I wrote about Capricor Therapeutics (CAPR) it was with respect to a Seeking Alpha article entitled "Capricor: Maintaining Hold Rating In Light of Deramiocel Complete Response Letter".

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

(RTTNews) - Shares of Inhibikase Therapeutics, Inc. (IKT) are up 12% at $1.72 in pre-market trading, after the company announced progress on its lead program alongside a major financing deal.

Novartis has spent considerable time and energy building its presence in the IgA nephropathy (IgAN) disease area, and now it can celebrate a key trial win for its first drug to gain an FDA approval in ...

The U.S. Space Force has selected SpaceX and United Launch Alliance to perform the first seven launches under the National Security Space Launch Program, or NSSL, Phase 3 Lane 2 contracts, Breaking ...